Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Pemetrexed Maintenance in Lung Adenocarcinoma
NCT02399566Phase 4Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of erlotinib in lung adenocarcinoma, sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
erlotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02399566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399566.